Science and Development Network
News, views and information about science, technology and the developing world
Links archive results 1-12 of 12 in Health and Drug development
A unit within the World Health Organization, IVR aims to develop and promote a global and sustainable research and development pipeline. This would deliver cost-effective vaccines against diseases that are particularly devastating in developing countries. The website provides a useful summary of...
LINK | 2 November 2005 | EN
This global non-profit organisation established by PATHhttp://www.path.org (the Programme for Appropriate Technology in Health) develops and tests potential malaria vaccines. The website contains background information on its malaria vaccine programme, including fact sheets, project and strategy...
LINK | 1 November 2005 | EN
The Institute of Human Virology, in Maryland, United States, is a multidisciplinary research institute dedicated to finding new treatments and vaccines for HIV, hepatitis C, and other diseases. Its main focus is basic and clinical HIV/AIDS research, including vaccine development. The website is...
LINK | 27 May 2004 | EN
The African AIDS Vaccine Programme was conceived in June 2000 as a network of African experts, working together to promote and facilitate HIV vaccine research and evaluation in Africa. Sponsored by WHO-UNAIDS, its mission is to advocate and support a coordinated effort to contribute to the global...
LINK | 27 May 2004 | EN
The Iberoamerican Bioinformatics Network brings together bioinformatics researchers from a number of Latin American nations and Spain. It aims to improve bioinformatics training, support high-quality research in the field of bioinformatics, and ensure that bioinformatics is kept up-to-date through...
LINK | 6 April 2004 | EN
The Global Campaign for Microbicides is an international organisation that aims to build awareness and political support for investment in microbides research and development, access and use. Its key activities are advocacy, policy analysis and social sciences research, in collaboration with...
LINK | 16 February 2004 | EN
IAVI is a global organisation working to speed the development and distribution of preventive AIDS vaccines. IAVI’s work focuses on: mobilising support through advocacy and education; accelerating scientific progress; encouraging industrial participation in AIDS vaccine development; and assuring...
LINK | 27 October 2003 | EN
The New York-based Aaron Diamond AIDS Research Center conducts basic research and clinical trials on HIV/AIDS, and is affiliated to The Rockefeller University. The website contains a brief fact sheet and a particularly clear graphical illustration of the stages of the HIV life...
LINK | 27 October 2003 | EN
The HIV Vaccine Trials Network is an international collaboration of scientists from more than 20 institutions worldwide developing and testing HIV vaccines in all phases of clinical trials. The website contains an excellent searchable databasehttp://chi.ucsf.edu/vaccines/ of ongoing trials,...
LINK | 27 October 2003 | EN
A European Union-funded collaboration between more than 20 laboratories in France, Italy, Germany, the Netherlands, Spain, Sweden, Switzerland, and the United Kingdom to bring European preventive HIV vaccines into Phase I clinical trials.
LINK | 27 October 2003 | EN
Applied Clinical Trials is a journal aimed at the global community of pharmaceutical and medical professionals who design, initiate, manage, conduct, and monitor clinical trials in the tightly regulated, highly competitive pharmaceutical industry. Some of the articles are relevant to developing...
LINK | 22 May 2003 | EN
The IFPMA represents the worldwide research-based pharmaceutical industry and other manufacturers of prescription medicines. The membership consists of national industry associations from both developed and developing countries, and corporations. The website contains IFPMA position papers on patent...
LINK | 1 May 2003 | EN
Our blog, by SciDev.Net columnist Priya Shetty, will fill you in, as will our interview with the Global Forum's Gill Samuels